Compounds > gliclazide

gliclazide and glucagon

gliclazide has been researched along with glucagon in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (14.29)	18.7374
1990's	6 (42.86)	18.2507
2000's	3 (21.43)	29.6817
2010's	1 (7.14)	24.3611
2020's	2 (14.29)	2.80

Authors

Authors	Studies
Ambrosi, F; Cristallini, S; Filipponi, P; Gregorio, F; Pedetti, M; Santeusanio, F	1
Kawai, K; Murayama, Y; Suzuki, S; Watanabe, Y; Yamashita, K	1
Gagliardino, JJ; Gronda, CM; Rossi, JP	1
Brogard, JM; Dorner, M; Pinget, M	1
Abiru, N; Akazawa, S; Ishibasi, M; Kawasaki, E; Matsumoto, K; Matsuo, H; Uotani, S; Yamamoto, H; Yamasaki, H; Yano, M	1
Hara, M; Sasaki, H; Takahashi, K; Yamatani, K	1
de Kreutzenberg, SV; Del Prato, S; Lisato, G; Marchetto, S; Riccio, A; Tiengo, A; Turrin, M	1
Hansen , AP; Juhl, CB; Pincus, SM; Pørksen, N; Schmitz, O; Veldhuis, JD	1
Cejvan, K; Cerasi, E; Coy, DH; Efendic, S; Holst, JJ	1
Caumo, A; Cobelli, C; Singhal, P; Taylor, R	1
Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D	1
Eggert, F; Elgert, C; Früh, E; Rustenbeck, I; Scherneck, S	1
Chae, H; Desmet, L; Gilon, P; Herrera, PL; Khattab, F; Singh, B	1
Burgstahler, AD; Mennone, A; Nathanson, MH; Rios-Velez, L	1

Trials

4 trial(s) available for gliclazide and glucagon

Article	Year
Insulin response after treatment depends on fasting plasma glucose level in NIDDM. Diabetes research and clinical practice, 1994, Dec-16, Volume: 26, Issue:2 Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting; Female; Gliclazide; Glucagon; Glucose Tolerance Test; Glyburide; Humans; Insulin; Male; Middle Aged	1994
Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients. Metabolism: clinical and experimental, 1996, Volume: 45, Issue:10 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gliclazide; Glucagon; Glucose; Hormones; Humans; Hypoglycemic Agents; Insulin; Kinetics; Liver; Male; Middle Aged; Osmolar Concentration; Somatostatin	1996
Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. Diabetes, 2001, Volume: 50, Issue:8 Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Entropy; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Middle Aged; Placebos; Prospective Studies; Time Factors	2001
Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. Metabolism: clinical and experimental, 2005, Volume: 54, Issue:1 Topics: Adult; Carbamates; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Gliclazide; Glucagon; Glucose; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Oxidation-Reduction; Piperidines; Postprandial Period	2005

Other Studies

10 other study(ies) available for gliclazide and glucagon

Article	Year
Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function. Diabetes research and clinical practice, 1992, Volume: 18, Issue:3 Topics: Animals; Blood Glucose; Dose-Response Relationship, Drug; Gliclazide; Glucagon; Glucose; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Perfusion; Rats; Rats, Sprague-Dawley; Sulfonylurea Compounds; Time Factors; Tolbutamide	1992
Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats. Diabetes research and clinical practice, 1991, Volume: 12, Issue:3 Topics: Animals; Animals, Newborn; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eating; Gliclazide; Glucagon; Glucose Tolerance Test; Insulin; Islets of Langerhans; Male; Pancreas; Rats; Rats, Inbred Strains; Streptozocin; Time Factors	1991
Effect of different insulin secretagogues and blocking agents on islet cell Ca2+-ATPase activity. Biochimica et biophysica acta, 1988, Aug-18, Volume: 943, Issue:2 Topics: Animals; Calcium-Transporting ATPases; Caproates; Cell Membrane; Gliclazide; Glucagon; Glucose; Insulin; Insulin Secretion; Islets of Langerhans; Keto Acids; Kinetics; Male; Rats; Somatostatin; Theophylline; Tolbutamide	1988
Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics. Current medical research and opinion, 1984, Volume: 9, Issue:1 Topics: Adult; Arginine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Gliclazide; Glucagon; Glucose Tolerance Test; Humans; Insulin; Insulin Secretion; Iodine Radioisotopes; Male; Middle Aged; Sulfonylurea Compounds; Time Factors	1984
Gliclazide directly suppresses arginine-induced glucagon secretion. Diabetes research and clinical practice, 1994, Volume: 24, Issue:3 Topics: Animals; Arginine; Cysteamine; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Interactions; Gliclazide; Glucagon; Insulin; Insulin Secretion; Male; Pancreas; Rats; Rats, Wistar; Somatostatin; Streptozocin; Sulfonylurea Compounds	1994
Gliclazide directly inhibits arginine-induced glucagon release. Diabetes, 2002, Volume: 51 Suppl 3 Topics: Animals; Arginine; Gliclazide; Glucagon; In Vitro Techniques; Islets of Langerhans; Male; Pancreas; Peptides, Cyclic; Rats; Rats, Wistar; Receptors, Somatostatin; Somatostatin; Sulfonylurea Compounds	2002
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. The Journal of clinical endocrinology and metabolism, 2017, 05-01, Volume: 102, Issue:5 Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors	2017
Glucagonotropic and Glucagonostatic Effects of KATP Channel Closure and Potassium Depolarization. Endocrinology, 2021, 01-01, Volume: 162, Issue:1 Topics: Animals; Arginine; Calcium; Cell Membrane; Female; Gliclazide; Glucagon; Glucagon-Secreting Cells; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; KATP Channels; Membrane Potentials; Mice; Potassium; Potassium Chloride; Tolbutamide	2021
K Molecular metabolism, 2021, Volume: 53 Topics: Animals; Calcium; Gliclazide; Glucagon; Glucagon-Secreting Cells; KATP Channels; Mice; Mice, Knockout; Mice, Transgenic; Potassium Channel Blockers; Somatostatin; Tolbutamide	2021
Communication via gap junctions modulates bile secretion in the isolated perfused rat liver. Gastroenterology, 1999, Volume: 116, Issue:5 Topics: Animals; Bile; Bucladesine; Calcium; Calcium-Transporting ATPases; Cell Communication; Enzyme Inhibitors; Fluoresceins; Gap Junctions; Glucagon; Glucose; Glycyrrhetinic Acid; Hydroquinones; In Vitro Techniques; Liver; Male; Perfusion; Rats; Rats, Sprague-Dawley; Vasopressins	1999